Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.

Mol Cancer Ther · 2021 · PMC9662933 · PMID 34518295

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an interesting trendno p-value reported

We have demonstrated an interesting trend in PD-L1, a biomarker of immunotherapy response, which was higher in patients with KRAS- mutant/ U2AF1 -mutant NSCLC (3% of KRAS -mutant cohort) compared with KRAS -mutant/ U2AF1 WT.

also in 1,783 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.